Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the anti-tumor activity, safety, tolerability, immunogenicity,
pharmacokinetics, and pharmacodynamics of imgatuzumab, a monoclonal antibody against
epidermal growth factor receptor (EGFR) with enhanced antibody-dependent cellular
cytotoxicity (ADCC) in patients with advanced cutaneous squamous cell carcinoma (CSCC).
Quality of life of patients treated with imgatuzumab will also be assessed.